Structural genomics approach to drug discovery for Mycobacterium tuberculosis

Current Opinion in Microbiology

Volumn 12, Issue 3, 2009, Pages 318-325

  Ioerger, Thomas R ^a   Sacchettini, James C ^b  

^a Texas AandM University   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL STRUCTURE; DIFFRACTION; DRUG RESEARCH; GENOME; HIGH THROUGHPUT SCREENING; INFORMATION PROCESSING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; STRUCTURAL GENOMICS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG DISCOVERY; GENOME, BACTERIAL; GENOMICS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 66349100409     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2009.04.006     Document Type: Review

References (63)

1. Hendrickson W., and Ogata C. Phase determination from multiwavelength anomalous diffraction measurements. Methods Enzymol 276 (1997) 494-523
2. Dauter Z. New approaches to high-throughput phasing. Curr Opin Struct Biol 12 (2002) 674-678
3. Adams P.D., Pannu N.S., Read R.J., and Brünger A.T. Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement. Proc Natl Acad Sci U S A 94 May (10) (1997) 5018-5023
4. Terwilliger T.C., and Berendzen J. Automated MAD and MIR structure solution. Acta Crystallogr D55 (1999) 849-861
5. Morris R.J., Perrakis A., and Lamzin V.S. ARP/wARP and automatic interpretation of protein electron density maps. Methods Enzymol 374 (2003) 229-244
6. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., and Read R.J. Phaser crystallographic software. J Appl Cryst 40 (2007) 658-674
7. Manjasetty B.A., Turnbull A.P., Panjikar S., Büssow K., and Chance M.R. Automated technologies and novel techniques to accelerate protein crystallography for structural genomics. Proteomics 8 February (4) (2008) 612-625. A review of high-throughput methods for structural genomics, ranging from protein production and crystallization, to data collection and processing.
8. Burley S.K., Almo S.C., Bonanno J.B., Capel M., Chance M.R., Gaasterland T., Lin D., Sali A., Studier F.W., and Swaminathan S. Structural genomics: beyond the human genome project. Nature Genet 23 (1999) 151-157
9. Chothia C. Proteins. One thousand families for the molecular biologist. Nature 357 June (6379) (1992) 543-544
10. Grant A., Lee D., and Orengo C. Progress towards mapping the universe of protein folds. Genome Biol 5 5 (2004) 107
11. Liu J., Hegyi H., Acton T.B., Montelione G.T., and Rost B. Automatic target selection for structural genomics on eukaryotes. Proteins 56 August (2) (2004) 188-200
12. Finn R.D., Tate J., Mistry J., Coggill P.C., Sammut J.S., Hotz H.R., Ceric G., Forslund K., Eddy S.R., Sonnhammer E.L., and Bateman A. The Pfam protein families database. Nucleic Acids Res 36 (2008) D281-D288
13. Kelley L.A., and Sternberg M.J.E. Protein structure prediction on the web: a case study using the Phyre server. Nat Protoc 4 (2009) 363-371
14. Schmid M.B. Seeing is believing: the impact of structural genomics on antimicrobial drug discovery. Nat Rev Microbiol 2 (2004) 739-746
15. Weigelt J., McBroom-Cerajewski L.D., Schapira M., Zhao Y., and Arrowmsmith C.H. Structural genomics and drug discovery: all in the family. Curr Opin Chem Biol 12 February (1) (2008) 32-39
16. Congreve M., Murray C.W., and Blundell T.L. Structural biology and drug discovery. Drug Discov Today 10 July (13) (2005) 895-907
17. Barker J.J. Antibacterial drug discovery and structure-based design. Drug Discov Today 11 May (9-10) (2006) 391-404
18. Nair R., Liu J., Soong T.T., Acton T.B., Everett J.K., Kouranov A., Fiser A., Godzik A., Jaroszewski L., Orengo C., Montelione G.T., and Rost B. Structural genomics is the largest contributor of novel structural leverage. J Struct Funct Genomics 1 April (2) (2009) 181-191. Up-to-date statistics on protein structures contributed to the RCSB by Structural Genomics Centers.
19. Strong M., Sawaya M.R., Wang S., Phillips M., Cascio D., and Eisenberg D. Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103 May (21) (2006) 8060-8065. Describes a large-scale screening effort to identify complexes between PPE and PGRS proteins that could be crystallized and solved. This is the first crystal structure from each of these highly duplicated families in the TB genome, whose function remains obscure.
20. Columbus L., Lipfert J., Klock H., Millett I., Doniach S., and Lesley S.A. Expression, purification, and characterization of Thermotoga maritima membrane proteins for structure determination. Protein Sci 15 May (5) (2006) 961-975
21. Arcus V.L., Lott J.S., Johnston J.M., and Baker E.N. The potential impact of structural genomics on Mycobacterium tuberculosis drug discovery. Drug Discov Today 11 (2006) 28-34
22. Murillo A.C., Li H.Y., Alber T., Baker E.N., Berger J.M., Cherney L.T., Cherney M.M., Cho Y.S., Eisenberg D., Garen C.R., et al. High throughput crystallography of TB drug targets. Infect Disord Drug Targets 7 June (2) (2007) 127-139. This review contains additional details about the high-throughput technologies used in the Tuberculosis Structural Genomics Consortium.
23. World Health Organization: Global tuberculosis control-epidemiology, strategy, financing. http://www.who.int/tb/publications/global_report/2009/en/index.html, accessed on 3/29/2009.
24. Jassal M., and Bishai W.R. Extensively drug-resistant tuberculosis. Lancet Infect Dis 9 January (1) (2009) 19-30. A recent review of XDR-TB, including world-wide epidemiology, genome sequence analysis of drug-resistance mutations, and clinical aspects.
25. Gomez J.E., and McKinney J.D. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 84 1-2 (2004) 29-44
26. Russell D.G. Who puts the tubercle in tuberculosis?. Nat Rev Microbiol 5 January (1) (2007) 39-47
27. Johnston J.M., Arcus V.L., Morton C.J., Parker M.W., and Baker E.N. Crystal structure of a putative methyltransferase from Mycobacterium tuberculosis: misannotation of a genome clarified by protein structural analysis. J Bacteriol 185 July (14) (2003) 4057-4065
28. Lee K., Zhan X., Gao J., Qiu J., Feng Y., Meganathan R., Cohen S.N., and Georgiou G. RraA: a protein inhibitor of RNase E activity that globally modulates RNA abundance in E. coli. Cell 114 September (5) (2003) 623-634
29. ® vector and expression protocol for fast and efficient recombinant protein expression in Mycobacterium smegmatis. Protein Expr Purif 57 (2008) 81-87. Describes an efficient system for cloning genes in preparation for subsequent expression and crystallization. All ∼4000 genes in the tuberculosis genome have been cloned into Gateway vectors.
30. Bursey E.H., Kim C.-Y., Yu M., Terwilliger T.C., and Hung L.-W. An automated high-throughput screening method for the identification of high-yield, soluble protein variants using cell-free expression and systematic truncation. J Struct Funct Genomics 7 3-4 (2006) 139-147
31. Yang J.K., Park M.S., Waldo G.S., and Suh S.W. Directed evolution approach to a structural genomics project: Rv2002 from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 100 January (2) (2003) 455-460
32. Goldschmidt L., Cooper D., Derewenda Z., and Eisenberg D. Toward rational protein crystallization: a Web server for the design of crystallizable protein variants. Protein Sci 16 (2007) 1569-1576. Describes the method of Surface Entropy Reduction for identifying mutations to make in proteins to facilitate crystallization.
33. Rupp B., Segelke B.W., Krupka H.I., Lekin T., Schäfer J., Zemla A., Toppani D., Snell G., and Earnest T. The TB structural genomics consortium crystallization facility: towards automation from protein to electron density. Acta Crystallogr D58 (2002) 1514-1518
34. Hansen C.L., Skordalakes E., Berger J.M., and Quake S.R. A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion. Proc Natl Acad Sci U S A 99 (2002) 16531-16536
35. Adams P.D., Grosse-Kunstleve R.W., Hung L.-W., Ioerger T.R., McCoy A.J., Moriarty N.W., Read R.J., Sacchettini J.C., Sauter N.K., and Terwilliger T.C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D58 (2002) 1948-1954
36. Hasan S., Daugelat S., Rao P.S., and Schreiber M. Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput Biol 2 June (6) (2006) e61
37. Sassetti C.M., Boyd D.H., and Rubin E.J. Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci U S A 98 June (22) (2001) 12712-12717
38. Smith D.A., Parish T., Stoker N.G., and Bancroft G.J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 69 (2001) 1142-1150
39. Lee C.E., Goodfellow C., Javid-Majd F., Baker E.N., and Shaun Lott J. The crystal structure of TrpD, a metabolic enzyme essential for lung colonization by Mycobacterium tuberculosis, in complex with its substrate phosphoribosylpyrophosphate. J Mol Biol 355 4 (2006) 784-797
40. Reddy M.C., Kuppan G., Shetty N.D., Owen J.L., Ioerger T.R., and Sacchettini J.C. Crystal structures of Mycobacterium tuberculosis S-adenosyl-L-homocysteine hydrolase in ternary complex with substrate and inhibitors. Protein Sci 17 12 (2008) 2134-2144. Describes the structure of M. tuberculosis SahH, which is an essential protein involved in re-cycling co-factor SAM used in methylation. Crystal complexes with several adenosine analogs are also reported for this potential drug target.
41. Mohamedmohaideen N.N., Palaninathan S.K., Morin P.M., Williams B.J., Braunstein M., Tichy S.E., Locker J., Russell D.H., Jacobs Jr. W.R., and Sacchettini J.C.L. Structure and function of the virulence-associated high-temperature requirement A of Mycobacterium tuberculosis. Biochemistry 47 23 (2008) 6092-6102
42. Wang F., Langley R., Gulten G., Wang L., and Sacchettini J.C. Identification of a type III thioesterase reveals the function of an operon crucial for Mtb virulence. Chem Biol 14 5 (2007) 543-551
43. Wang F., Cassidy C., and Sacchettini J.C. Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. Antimicrob Agents Chemother 50 8 (2006) 2762-2771
44. Hugonnet J.E., and Blanchard J.S. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 46 October (43) (2007) 11998-12004
45. Harrison A.J., Yu M., Gårdenborg T., Middleditch M., Ramsay R.J., Baker E.N., and Lott J.S. The structure of MbtI from Mycobacterium tuberculosis, the first enzyme in the biosynthesis of the siderophore mycobactin, reveals it to be a salicylate synthase. J Bacteriol 188 September (17) (2006) 6081-6091
46. Cherney L.T., Cherney M.M., Garen C.R., Niu C., Moradian F., and James M.N. Crystal structure of N-acetyl-gamma-glutamyl-phosphate reductase from Mycobacterium tuberculosis in complex with NADP(+). J Mol Biol 367 April (5) (2007) 1357-1369
47. Sankaranarayanan R., Cherney M.M., Cherney L.T., Garen C.R., Moradian F., and James M.N. The crystal structures of ornithine carbamoyltransferase from Mycobacterium tuberculosis and its ternary complex with carbamoyl phosphate and L-norvaline reveal the enzyme's catalytic mechanism. J Mol Biol 375 January (4) (2008) 1052-1063
48. Miallau L., Faller M., Chiang J., Arbing M., Guo F., Cascio D., and Eisenberg D. Structure and proposed activity of a member of the VapBC family of toxin-antitoxin systems: VapBC-5 from Mycobacterium tuberculosis. J Biol Chem 284 January (1) (2009) 276-283. The papers describes the first crystal structure of the complex of a toxin-antitoxin pair in the M. tuberculosis genome, in which there are 38 such pairs. Analysis of the structure of the toxin suggests that in may have a ribonuclease function.
49. Wang S., and Eisenberg D. Crystal structures of a pantothenate synthetase from M. tuberculosis and its complexes with substrates and a reaction intermediate. Protein Sci 12 May (5) (2003) 1097-1108
50. Wang S., and Eisenberg D. Crystal structure of the pantothenate synthetase from Mycobacterium tuberculosis, snapshots of the enzyme in action. Biochemistry 45 (2006) 1554-1561
51. White E.L., Southworth K., Ross L., Cooley S., Gill R.B., Sosa M.I., Manouvakhova A., Rasmussen L., Goulding C., Eisenberg D., and Fletcher III T.M. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J Biomol Screen 12 February (1) (2007) 100-105. This paper reports the discovery of nafronyl oxalate as an inhibitor of M. tuberculosis PanC, along with a crystal structure of the complex showing how it binds in the active site.
52. McKinney J.D., Höner zu Bentrup K., Muñoz-Elías E.J., Miczak A., Chen B., Chan W.T., Swenson D., Sacchettini J.C., Jacobs Jr. W.R., and Russell D.G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406 August (6797) (2000) 735-738
53. Smith C.V., Huang C.C., Miczak A., Russell D.G., Sacchettini J.C., and Höner zu Bentrup K. Biochemical and structural studies of malate synthase from Mycobacterium tuberculosis. J Biol Chem 278 January (3) (2003) 1735-1743
54. Carroll P., Muttucumaru D.G., and Parish T. Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Appl Environ Microbiol 71 June (6) (2005) 3077-3084
55. Bardarov Jr. S., Pavelka Jr. M.S., Sambandamurthy V., Larsen M., Tufariello J., Chan J., Hatfull G., and Jacobs Jr. W.R. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG, and M. smegmatis. Microbiology 148 (2002) 3007-3017
56. Larsen M.H., Vilchèze C., Kremer L., Besra G.S., Parsons L., Salfinger M., Heifets L., Hazbon M.H., Alland D., Sacchettini J.C., and Jacobs Jr. W.R. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 46 October (2) (2002) 453-466
57. Brosch R., Gordon S.V., Marmiesse M., Brodin P., Buchrieser C., Eiglmeier K., Garnier T., Gutierrez C., Hewinson G., Kremer K., et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 99 (2002) 3684-3689
58. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46 (2001) 3-26
59. Congreve M., Chessari G., Tisi D., and Woodhead A.J. Recent developments in fragment-based drug discovery. J Med Chem 51 13 (2008) 3661-3680
60. Klebe G. Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 11 (2006) 580-594
61. Cho Y., Ioerger T.R., and Sacchettini J.C. Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening. J Med Chem 51 19 (2008) 5984-5992. Describes the successful application of virtual screening to identify compounds that inhibit M. tuberculosis HisG based on a crystal structure of the complex with AMP and histidine.
62. Gillespie S.H. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46 February (2) (2002) 267-274
63. Vilchèze C., Av-Gay Y., Attarian R., Liu Z., Hazbón M.H., Colangeli R., Chen B., Liu W., Alland D., Sacchettini J.C., and Jacobs Jr. W.R. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol Microbiol 69 September (5) (2008) 1316-1329